Eric Langer

The industry may not be ready for India and China as regulatory issues emerge.

Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.

BioPlan's Annual Report shows continued growth in the use of single-use technology.

BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.

Growth is seen in outsourcing of insect- and plant-cell-based bioproduction expression systems.

Will international biomanufacturing outsourcing become mainstream in this decade?

Budgets for biopharma activities are gaining in select functional areas, except outsourcing.

Industry wants more innovation, but can suppliers meet customers' needs?

New outsourcing industry sectors have become multibillion-dollar industries.

Industry optimism is on the rise for 2012.

Biosimilar manufacturers need better expression systems and analytical tools to compete.

Single-use systems continue to gain traction among biomanufacturers, especially CMOs.

The BioPlan Associates 8th annual survey identifies key outsourcing concerns of sponsor companies.

China rises to the top as a destination for international outsourcing.

Insights from real-time ranking of global biomanufacturing capabilities.

A recent industry survey shows keen interest in improving bioreactors and cell-culture media.

Knowing where key biomanufacturing facilities are located around the world is essential for decision-making.

Can vendor-user partnerships overcome the typical wait-and-see attitude toward new technologies?

Although single-use systems are widely used in upstream unit operations, their acceptance in downstream processes has been slow.

Biomanufacturers and vendors are now exploring more cost-effective purification technologies.

The new technologies being developed to improve downstream systems go beyond traditional chromatography.

Gaining a license can be a complex process, but a few key tips can help you avoid common pitfalls and patent infringements.

Companies often wait for a critical mass before adopting new technologies. But if no one takes the risk, critical mass will never be reached.

With all of the new expressions systems being developed, companies must decide what improved production and yield are really worth.

If Indian biologics manufacturers can establish a track record for recombinant products, enhance quality image, maintain cost competitiveness, and demonstrate technology transfer and regulatory knowhow, they are likely to be in the middle of the next boom in biologics manufacturing.

The rapid growth of the pharmaceutical industry in India is yet to create significant changes in the Indian distribution system.

What the Indian government is doing to make its biotech sector as strong as its IT sector.

The bioinformatics industry is currently one of the fastest growing fields in India's biotechnology sector. Indian IT companies have several advantages in the bioinformation field and can continue to grow their opportunities worldwide.

India's biopharmaceutical industry, which was relatively modest only a decade ago, is expected to generate almost $2 billion in sales in 2008, making it one of the largest biopharmaceutical segments in Asia.1 According to BioPlan Associates, Inc., and the Society for Industrial Microbiology's newly published joint study, Advances in Biopharmaceutical Technology in India, the Indian biopharmaceutical industry is growing 25 to 30% per year.1

China's pharma industry represents 5% of the world total. By 2010, China is expected to become the world's fifth largest pharmaceutical market.